Hematology, Ampang Hospital, Ampang, Selangor, Malaysia
BMJ Case Rep. 2020 Jul 23;13(7):e235543. doi: 10.1136/bcr-2020-235543.
Plasma cell leukaemia (PCL) is an aggressive haematological malignancy which is classified into primary (pPCL) and secondary PCL. A 39-year-old Indian man presented to the Department of Hematology with a 2-week history of fever and lethargy. Clinically, he was pale and febrile. Haemogram revealed bicytopenia with leucocytosis. The peripheral blood film portrayed rouleax formation with 45% of circulating plasma cells. Serum protein electrophoresis and immunofixation revealed IgG lambda paraproteinaemia of 48 g/L. Bone marrow aspirate, flow cytometry and trephine were consistent with IgG lambda pPCL. He was treated with six cycles of bortezomib, thalidomide and dexamethasone combination chemotherapy followed by high-dose melphalan conditioning and autologous stem cell transplant. Currently, he is in complete remission for the past 18 months and is on oral lenalidomide maintenance therapy. Prognosis is often dismal in pPCL with the median overall survival below 1 year if treatment is delayed.
浆细胞白血病(PCL)是一种侵袭性血液系统恶性肿瘤,分为原发性(pPCL)和继发性 PCL。一名 39 岁的印度男性因发热和乏力就诊于血液科,病史为 2 周。临床检查发现患者面色苍白,发热。血常规显示双系细胞减少伴白细胞增多。外周血涂片显示 45%的循环浆细胞呈缗钱状排列。血清蛋白电泳和免疫固定电泳显示 IgG λ 型副蛋白血症,为 48g/L。骨髓抽吸、流式细胞术和活检与 IgG λ pPCL 一致。他接受了六周期硼替佐米、沙利度胺和地塞米松联合化疗,随后进行了大剂量马法兰预处理和自体干细胞移植。目前,他已完全缓解 18 个月,正在接受口服来那度胺维持治疗。如果治疗延迟,pPCL 的总体预后往往较差,中位总生存期不到 1 年。